Ginkgo Bioworks Q1 Revenue Plunges 49% to $19M, Plans to Double Nebula Lab
First quarter revenue fell 49% to $19M versus prior-year $38M, with GAAP net loss of $76M and Adjusted EBITDA of negative $42M. Ginkgo completed the April 3 divestiture of its Biosecurity unit, holds $373M in cash and plans to double its Nebula autonomous lab capacity this year.
1. First Quarter 2026 Financial Results
Ginkgo reported $19 million in revenue for Q1 2026, down 49% from $38 million a year earlier, reflecting a 37% decline on a like-for-like basis after excluding a $7 million deferred revenue release in Q1 2025. The company posted a GAAP net loss of $76 million and an Adjusted EBITDA loss of $42 million.
2. Biosecurity Business Divestiture
On April 3, Ginkgo completed the sale of its Biosecurity unit, reclassifying that segment’s results as discontinued operations. Prior-period financials have been recast to present Ginkgo as a single reporting segment focused on its core biology platform.
3. Autonomous Lab Expansion Plans
Ginkgo aims to accelerate adoption of its Nebula autonomous lab platform, currently the world’s largest, by doubling its capacity in 2026. Management highlights that each experiment run on Nebula generates immediate revenue and enhances the platform’s AI-driven workflows.
4. Cash Position and Outlook
As of March 31, Ginkgo held $373 million in cash, cash equivalents and marketable securities, and reaffirmed full-year 2026 cash burn guidance of $125 million to $150 million. The company projects this liquidity will support ongoing lab expansion and AI integration initiatives.